Clinical outcome following benralizumab discontinuation in patients with severe eosinophilic asthma: A single-center study
- 4 June 2026
- journal article
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4) , 101465
Abstract
No abstract availableKeywords
Funding Information
- Teijin Pharma
This publication has 12 references indexed in Scilit:
- Outcomes following the discontinuation of biologic therapy in patients with severe asthmaAllergology International, 2026
- Pro: Clinical remission in asthma – implications for asthma managementEuropean Respiratory Review, 2025
- Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practiceRespiratory Investigation, 2024
- Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)European Respiratory Journal, 2024
- Stoppingversuscontinuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)European Respiratory Journal, 2021
- Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma BiologicsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic AsthmaChest, 2020
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysisJournal of Allergy and Clinical Immunology, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012